Evidence map›Paper›PMID 42856926›Full record

ReviewFrontiers in bioengineering and biotechnology2026

From quiescence to hypertrophy: existing and emerging genetic targets to fine-tune myogenesis in cultivated muscle.

Lucy Wilkinson, David Tosh, Marianne Ellis

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lucy WilkinsonDepartment of Chemical Engineering, The University of Bath, Bath, United Kingdom.
David ToshDepartment of Life Sciences, The University of Bath, Bath, United Kingdom.
Marianne EllisDepartment of Chemical Engineering, The University of Bath, Bath, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cultivated meat (CM) offers a promising alternative to conventional meat with the potential to address the sustainability, animal welfare, and public health concerns associated with intensive animal agriculture. The scalability, economic viability and quality of a CM product are likely to be reliant on high-performing muscle cell lines capable of rapid proliferation, efficient differentiation and a high protein yield relative to culture volume. Although early research has prioritised the expansion of undifferentiated cell biomass, differentiated muscle cells will likely be important for replicating the structural and nutritional properties of conventional meat. Cell line engineering offers a powerful method to achieve this by enabling precise control over cellular functions while reducing the cost and complexity of a bioprocess. To date, cell line engineering has been deployed in the context of CM to improve cell characteristics, such as immortality, proliferation rate, or metabolic efficiency. However, many of the complex signalling pathways that regulate myogenesis and skeletal muscle hypertrophy remain underexplored in agriculturally-relevant cell lines. This review explores the key existing and emerging genetic targets for enhancing myogenesis in the context of CM, including TGF-β, MEK/ERK, PI3K/AKT/mTOR and Wnt signalling pathways. Engineering these pathways has the potential to fine-tune the balance between proliferation and differentiation or induce hypertrophy and increase protein yield without the need for costly media additives. The integration of advanced genome editing technologies with rigorous quality control and regulatory systems could significantly improve the performance of muscle-derived cells for scalable CM production.

Indexed as

cell line engineeringcell signallingcultivated meatmusclemyogenesissatellite cells

Identifiers

PMID42856926
PMCPMC13650544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.